In the past few years, our improved knowledge of acute myeloid leukemia (AML)
pathogenesis has led to the accelerated discovery of new drugs and the development of …

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are clonal
hematopoietic stem cell diseases leading to an insufficient formation of functional blood …

Chemoresistance contributes to poor survival and high relapse risk in acute myeloid
leukemia (AML). As a pro-inflammatory cytokine, interleukin-6 (IL-6) plays a vital role in the …

Bone marrow (BM) is a highly complex tissue that provides important regulatory signals to
orchestrate hematopoiesis. Resident and transient cells occupy and interact with some well …

Acute myeloid leukemia (AML) is a heterogeneous malignancy affecting myeloid cells in the
bone marrow (BM) but can spread giving rise to impaired hematopoiesis. AML incidence …

Background Acute myeloid leukemia (AML) is a hematological malignancy that remains a
therapeutic challenge due to the high incidence of disease relapse. To better understand …

Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis and
remarkable resistance to chemotherapeutic agents. Understanding resistance mechanisms …

Simple Summary Despite remarkable progress in the outcome of childhood acute myeloid
leukemia (AML), risk of relapse and refractory diseases remains high. Treatment of the …

Acute myeloid leukemia (AML) comprises a multifarious and heterogeneous array of
illnesses characterized by the anomalous proliferation of myeloid cells in the bone marrow …

Natural killer (NK) cells are prominent cytotoxic and cytokine-producing components of the
innate immune system representing crucial effector cells in cancer immunotherapy …